ARTICLE
23 December 2022

Health Canada Releases New Guidance Document On Clinical Evidence Requirements For Medical Devices

SB
Smart & Biggar

Contributor

Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients. Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights. As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
On November 15, 2022, Health Canada released a new guidance document, "Guidance on clinical evidence requirements for medical devices."
Canada Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

On November 15, 2022, Health Canada released a new guidance document, "Guidance on clinical evidence requirements for medical devices." In this document, Health Canada provides guidance on clinical evidence requirements for Class II, III, and IV medical devices. This document does not apply to in vitro diagnostic devices (IVDDs).

The document includes guidance on when clinical data/evidence is required, methods to generate and evaluate clinical data, and how to compare devices appropriately. It also provides general principles and criteria for clinical evidence that supports amending licence applications, and additional obligations during the post-market phase.

Health Canada also released a companion document, "Examples of clinical evidence requirements for medical devices," which contains examples of different types of devices and outlines when clinical evidence is more likely or less likely to be required.

Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More